CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
Hong Kong · Delayed Price · Currency is HKD 0.6050
+0.0050 (0.83%)
Aug 21, 2026, 4:08 PM HKT
HKG:0775 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,520 | 5,410 | 5,523 | 5,323 | 5,276 | 5,402 | |
Revenue Growth | 0.50% | -2.04% | 3.76% | 0.89% | -2.35% | 9.30% |
Cost of Revenue | 3,972 | 3,833 | 3,830 | 3,686 | 3,650 | 3,772 |
Gross Profit | 1,548 | 1,577 | 1,693 | 1,637 | 1,626 | 1,630 |
Selling, General & Admin | 720.97 | 705.67 | 655.4 | 593.38 | 536.56 | 571.56 |
Amortization of Goodwill & Intangibles | 2.68 | 2.47 | 2.51 | 2.55 | 3.17 | 7.59 |
Other Operating Expenses | 750.59 | 916.41 | 867.98 | 723.86 | 747.93 | 707.51 |
Operating Expenses | 1,559 | 1,708 | 1,615 | 1,413 | 1,386 | 1,393 |
Operating Income | -11.32 | -131.03 | 77.46 | 223.85 | 239.92 | 236.61 |
Interest Expense | -254.07 | -266.89 | -337.18 | -322.43 | -163.09 | -97.82 |
Interest & Investment Income | 17.24 | 21.2 | 13.9 | 13.18 | 5.78 | 1.43 |
Earnings From Equity Investments | -0.34 | 0.36 | 0.15 | 0.33 | 0.02 | 1.21 |
Currency Exchange Gain (Loss) | 1.29 | 1.29 | -4.2 | -11.52 | -3.48 | 4.21 |
Other Non Operating Income (Expenses) | 52.76 | 64.46 | 45.08 | 31.52 | 27.79 | 28.77 |
EBT Excluding Unusual Items | -194.44 | -310.61 | -204.8 | -65.06 | 106.95 | 174.4 |
Impairment of Goodwill | -147.79 | -147.79 | - | - | - | - |
Gain (Loss) on Sale of Investments | 0.76 | 0.66 | 5.4 | -0.35 | 0.52 | -1.05 |
Gain (Loss) on Sale of Assets | 693.46 | 693.46 | 244.83 | 94.63 | 51.51 | -0.76 |
Asset Writedown | -253.72 | -253.72 | -136.91 | 39.37 | 43.72 | 61.13 |
Other Unusual Items | - | - | - | - | 2.16 | 4.52 |
Pretax Income | 98.26 | -18.01 | -91.48 | 68.58 | 204.86 | 238.24 |
Income Tax Expense | 184.5 | 170.44 | 35.07 | 51.33 | 72.91 | 75.44 |
Earnings From Continuing Operations | -86.24 | -188.45 | -126.55 | 17.25 | 131.95 | 162.8 |
Minority Interest in Earnings | 21.54 | 1.64 | - | - | 0.01 | - |
Net Income | -64.7 | -186.81 | -126.55 | 17.25 | 131.96 | 162.8 |
Net Income to Common | -64.7 | -186.81 | -126.55 | 17.25 | 131.96 | 162.8 |
Net Income Growth | - | - | - | -86.93% | -18.94% | 30.00% |
Shares Outstanding (Basic) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 |
Shares Outstanding (Diluted) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | -0.01 | -0.02 | -0.01 | 0.00 | 0.01 | 0.02 |
EPS (Diluted) | -0.01 | -0.02 | -0.01 | 0.00 | 0.01 | 0.02 |
EPS Growth | - | - | - | -86.93% | -18.94% | 30.29% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -101.98 | -58.03 | 157.01 | 226.51 | 147.64 | 207.37 |
Free Cash Flow Per Share | -0.01 | -0.01 | 0.02 | 0.02 | 0.01 | 0.02 |
Dividend Per Share | - | - | - | - | 0.008 | 0.010 |
Dividend Growth | - | - | - | - | -20.00% | 0% |
Gross Margin | 28.04% | 29.15% | 30.65% | 30.76% | 30.82% | 30.17% |
Operating Margin | -0.21% | -2.42% | 1.40% | 4.21% | 4.55% | 4.38% |
Profit Margin | -1.17% | -3.45% | -2.29% | 0.32% | 2.50% | 3.01% |
Free Cash Flow Margin | -1.85% | -1.07% | 2.84% | 4.25% | 2.80% | 3.84% |
EBITDA | 194.14 | 31.5 | 243.94 | 380.71 | 393.78 | 400.34 |
EBITDA Margin | 3.52% | 0.58% | 4.42% | 7.15% | 7.46% | 7.41% |
D&A For EBITDA | 205.46 | 162.53 | 166.47 | 156.86 | 153.86 | 163.73 |
EBIT | -11.32 | -131.03 | 77.46 | 223.85 | 239.92 | 236.61 |
EBIT Margin | -0.21% | -2.42% | 1.40% | 4.21% | 4.55% | 4.38% |
Effective Tax Rate | 187.77% | - | - | 74.85% | 35.59% | 31.66% |